Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Ceo-two
Generic Name
Laxative
Active Ingredient
Potassium BitartrateCategory
Calculi Dissolution Agent [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| .9 g/5.7g | SUPPOSITORY | RECTAL | 0283-1023 |
Detailed information about Ceo-two
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ceo-two, you must consult a qualified healthcare professional.
Potassium Bitartrate, commonly known as cream of tartar, is a versatile pharmacological agent used as a calculi dissolution agent, an acidifier, and a carbon dioxide-releasing laxative. It plays critical roles in gastrointestinal health and as a buffer in various therapeutic preparations.
The dosage of Potassium Bitartrate varies significantly based on the intended use. For the treatment of constipation via rectal administration, the following guidelines typically apply:
Oral dosing for acidification or other purposes is rare in modern clinical practice and must be strictly supervised by a physician, as high oral doses can lead to hyperkalemia (high potassium levels) or severe diarrhea.
Potassium Bitartrate must be used with caution in pediatric populations.
Patients with significant renal impairment (kidney disease) must use Potassium Bitartrate with extreme caution. While rectal absorption is low, any systemic uptake of potassium could lead to hyperkalemia, a dangerous condition where potassium levels in the blood become too high. Dose frequency should be minimized, and serum potassium levels should be monitored if use is frequent.
No specific dosage adjustments are typically required for patients with liver disease, as the metabolism of Potassium Bitartrate does not heavily rely on hepatic pathways. However, patients with end-stage liver disease and associated renal issues (hepatorenal syndrome) should be treated with the same caution as renal patients.
Geriatric patients are at a higher risk for dehydration and electrolyte imbalances. While CO2-releasing suppositories are generally safer than stimulant laxatives, elderly patients should be monitored for signs of rectal irritation or excessive fluid loss if they experience multiple bowel movements.
For rectal suppositories:
Since Potassium Bitartrate is typically used on an 'as-needed' basis for constipation, missed doses are generally not a concern. If your doctor has prescribed a specific schedule and you miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose. Do not double the dose to catch up.
An overdose of Potassium Bitartrate is rare when used rectally. However, if the powder is ingested orally in large quantities, signs of overdose may include:
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency of use without medical guidance.
When used as a rectal suppository, the most common side effects are localized to the site of administration. These include:
> Warning: Stop taking Potassium Bitartrate and call your doctor immediately if you experience any of these serious symptoms.
Potassium Bitartrate is not intended for long-term, daily use. Chronic use of any laxative, including CO2-releasing suppositories, can lead to:
At this time, there are no FDA black box warnings for Potassium Bitartrate. It is generally recognized as safe (GRAS) by the FDA for food use and has a long history of safe clinical use when used as directed. However, this does not mean the drug is without risk, particularly for those with kidney disease or intestinal blockages.
Report any unusual symptoms or side effects that persist to your healthcare provider to ensure they are documented and managed appropriately.
Potassium Bitartrate should be used only for the indications for which it was intended. Patients should be aware that rectal suppositories are for rectal use only and should never be taken by mouth. If accidental ingestion occurs, medical advice should be sought immediately due to the risk of rapid potassium elevation.
No FDA black box warnings for Potassium Bitartrate currently exist. However, clinical guidelines emphasize that it should not be used as a primary treatment for chronic constipation without a full diagnostic workup by a gastroenterologist.
For most patients using Potassium Bitartrate occasionally, no special lab tests are required. However, for specific populations, the following may be necessary:
Potassium Bitartrate does not typically cause drowsiness or cognitive impairment. However, the sudden and strong urge to have a bowel movement after using a suppository means patients should ensure they have immediate access to a restroom and should not be driving or operating machinery during the 30-60 minutes following administration.
There are no direct chemical interactions between alcohol and Potassium Bitartrate. However, alcohol is a diuretic and can contribute to dehydration, which worsens constipation. It is recommended to limit alcohol intake when treating gastrointestinal issues.
There is no withdrawal syndrome associated with stopping Potassium Bitartrate. However, if you have been using it frequently, you may experience a 'rebound' period of constipation. It is best to taper off use by increasing dietary fiber and fluid intake under a doctor's supervision.
> Important: Discuss all your medical conditions, especially kidney disease or heart problems, with your healthcare provider before starting Potassium Bitartrate.
There are few absolute contraindications for the local use of Potassium Bitartrate; however, the following should be avoided:
For each interaction, the clinical consequence is usually a disruption in electrolyte balance or a reduction in the efficacy of one of the agents. Management involves spacing the doses or choosing an alternative laxative that does not contain potassium (such as glycerin suppositories).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any history of kidney or heart disease.
Potassium Bitartrate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a physician include:
Patients who have had allergic reactions to Non-Standardized Food Allergenic Extracts [EPC] or other tartrate-containing medications (such as Potassium Sodium Tartrate or 'Rochelle Salt') should be considered at risk for cross-sensitivity. While tartaric acid is found naturally in many fruits (especially grapes), the concentrated pharmaceutical form may trigger reactions in highly sensitive individuals.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'silent' kidney disease, before prescribing or recommending Potassium Bitartrate.
Potassium Bitartrate is generally considered safe for use during pregnancy when used rectally for occasional constipation. It is not known to be teratogenic (causing birth defects). Because it acts locally and releases carbon dioxide, it does not typically enter the bloodstream in amounts that would affect the fetus. However, pregnant women should always consult their OB/GYN before using any medication, as maintaining proper hydration and electrolyte balance is critical during gestation. It is often preferred over stimulant laxatives like senna, which can cause uterine contractions.
Potassium Bitartrate is compatible with breastfeeding. The components (potassium and tartrate) are natural constituents of the human diet. The amount of potassium that might reach breast milk from a rectal suppository is negligible compared to dietary intake. There are no known adverse effects on the nursing infant.
As noted in the dosage section, Potassium Bitartrate is generally reserved for children over 6 years of age under medical supervision. In children, the rectal mucosa is thinner and more sensitive, meaning the 'burning' sensation from the CO2 release may be more distressing. Pediatricians often recommend glycerin suppositories as a first-line rectal treatment before moving to CO2-releasing agents.
In the elderly, the primary concerns are renal function and the risk of falls. If an elderly patient uses a suppository and experiences a sudden, strong urge to defecate, they may be at risk of a fall while rushing to the bathroom. Furthermore, as renal function naturally declines with age, the risk of hyperkalemia must be considered if the product is used frequently. Healthcare providers should assess the GFR of elderly patients before recommending long-term or frequent use.
This is the most critical special population for Potassium Bitartrate. In patients with a GFR below 30 mL/min/1.73m², the use of any potassium-containing medication should be strictly limited. If use is absolutely necessary, serum potassium must be monitored within 24 hours of administration to ensure levels remain within the safe range (3.5–5.0 mEq/L).
While there are no specific dose adjustments for liver disease, patients with cirrhosis often have secondary electrolyte disturbances (such as low sodium or high potassium if they are on spironolactone). Therefore, the 'total potassium load' must be calculated by the physician when managing constipation in these patients.
> Important: Special populations, particularly the elderly and those with kidney issues, require an individualized medical assessment to determine the safest course of treatment.
Potassium Bitartrate ($KC_4H_5O_6$) functions primarily through its chemical reactivity and its role as an acidifying agent. In the rectum, it acts as a reactant. When combined with sodium bicarbonate ($NaHCO_3$) in a suppository base, it remains stable until it contacts the moisture of the rectal mucosa. The hydrogen ion from the bitartrate reacts with the bicarbonate ion to produce carbonic acid, which rapidly dissociates into water and carbon dioxide gas. The gas creates an immediate mechanical stimulus.
In its role as a Calculi Dissolution Agent, it acts as a urinary acidifier. By increasing the concentration of hydrogen ions in the urine, it can increase the solubility of calcium phosphate and other minerals that are less soluble in alkaline environments.
| Parameter | Value |
|---|---|
| Bioavailability | <5% (Rectal); High (Oral Potassium) |
| Protein Binding | Negligible |
| Half-life | 1-2 hours (Systemic Tartrate) |
| Tmax | 15-30 minutes (Local Effect) |
| Metabolism | Minimal (Intestinal Microflora) |
| Excretion | Fecal (Major); Renal (Minor) |
Potassium Bitartrate is categorized as a Calculi Dissolution Agent [EPC] and a Gastrointestinal Agent, Stimulant. It is related to other tartrate salts like Sodium Tartrate and Potassium Sodium Tartrate, though it is the most commonly used in the CO2-releasing suppository class.
Common questions about Ceo-two
Potassium Bitartrate is primarily used in clinical settings as a rapid-acting laxative in the form of rectal suppositories to treat occasional constipation. It works by reacting with sodium bicarbonate to release carbon dioxide gas, which gently stimulates the rectal walls to trigger a bowel movement. Additionally, it is used as an acidifying agent in various medications to maintain their stability and as a buffer in allergenic extracts. Historically, it has also been classified as a calculi dissolution agent for managing certain types of kidney stones. Your doctor may also use it as part of a bowel preparation routine before certain medical procedures.
The most common side effects of Potassium Bitartrate, particularly when used as a suppository, include mild rectal burning, stinging, or a general sense of discomfort at the site of insertion. Many patients also experience a very strong or sudden urge to have a bowel movement, which is the intended clinical effect. Some individuals may report mild abdominal cramping or gas-like sensations in the lower pelvic area. These symptoms are typically transient and resolve immediately after the bowels are evacuated. If you experience severe pain or persistent bleeding, you should contact your healthcare provider immediately.
While there is no direct chemical interaction between alcohol and Potassium Bitartrate, it is generally advised to limit alcohol consumption when dealing with constipation. Alcohol is a diuretic, which can lead to dehydration and further harden the stool, making the laxative less effective or causing the constipation to return. Furthermore, if you are using Potassium Bitartrate for its acidifying properties, alcohol may interfere with your body's overall pH balance and hydration status. Always consult your doctor about your alcohol intake if you have underlying kidney or heart conditions. For occasional rectal use, a single drink is unlikely to cause a major interaction, but staying hydrated with water is much more beneficial for your gastrointestinal health.
Potassium Bitartrate is generally considered safe for use during pregnancy, especially when used rectally, as it acts locally and has very low systemic absorption. It is often preferred by obstetricians over stimulant laxatives because it does not cause the systemic effects or uterine contractions that some other agents might. However, because every pregnancy is unique, it is vital to discuss the use of any laxative with your healthcare provider first. They will ensure that your constipation isn't a sign of a more complex issue and that the medication won't interfere with your prenatal vitamins or other treatments. Maintaining high fluid intake and a fiber-rich diet is always the first recommendation for pregnant women.
When administered as a CO2-releasing rectal suppository, Potassium Bitartrate works very quickly, typically producing a bowel movement within 15 to 30 minutes. The chemical reaction that releases the carbon dioxide gas begins almost immediately upon contact with the moisture in the rectum. For the best results, patients are usually advised to remain lying down and try to retain the suppository for at least 15 minutes, even if the urge to go is strong. This ensures that enough gas is produced to fully stimulate the defecation reflex. If no movement occurs within an hour, you should consult your doctor rather than using a second dose immediately.
Yes, you can stop taking Potassium Bitartrate suddenly, as it is not a medication that causes physical withdrawal or requires tapering. It is most often used on an as-needed basis for acute episodes of constipation rather than as a daily maintenance drug. However, if you have been using it frequently, your body may have become accustomed to the extra stimulation, and you might experience a temporary return of constipation. To prevent this, it is important to gradually increase your natural fiber intake and stay well-hydrated. If you find that you cannot have a bowel movement without the use of a suppository, you should see a doctor to rule out chronic conditions.
Because Potassium Bitartrate is typically used only when needed for constipation, a 'missed dose' is rarely a clinical concern. You should simply use the medication when you next feel the need for it, following the instructions on the package. If your healthcare provider has put you on a specific schedule (for example, for bowel surgery preparation) and you miss a dose, you should contact their office for instructions. Do not use two suppositories at once to make up for a missed one, as this can cause excessive rectal irritation or cramping. Always follow the specific timing provided by your medical team for diagnostic procedures.
There is no clinical evidence to suggest that Potassium Bitartrate causes weight gain. When used rectally as a laxative, it has almost no systemic absorption and does not affect your metabolism, fat storage, or appetite. In fact, laxatives are sometimes associated with temporary weight loss due to the evacuation of stool and water, though this is not a healthy or permanent way to manage weight. If you experience sudden weight gain while using any medication, it is more likely related to fluid retention or an underlying health condition. You should discuss any unexpected changes in your weight with your healthcare provider.
Potassium Bitartrate can interact with certain medications, particularly those that affect potassium levels in the blood. If you are taking ACE inhibitors, potassium-sparing diuretics (like spironolactone), or heart medications like Digoxin, you must consult your doctor before using Potassium Bitartrate. While rectal absorption is low, the risk of hyperkalemia (high potassium) is a serious concern for people with kidney disease or those on these specific drugs. It is also generally recommended to avoid using multiple different types of laxatives at the same time unless directed by a physician. Always provide your doctor or pharmacist with a full list of your current medications and supplements.
Potassium Bitartrate is widely available both as a generic substance and as a key ingredient in several brand-name products. In the pharmacy, you will most commonly find it as a generic 'Cream of Tartar' powder or as a component in branded CO2-releasing suppositories like CEO-Two. Because it is a simple chemical compound, generic versions are just as effective as brand-name versions for the treatment of constipation. It is also found as an inactive ingredient in many other generic and brand-name medications where it serves as a buffer or stabilizer. Always check the 'Active Ingredients' section of the label to confirm the concentration of Potassium Bitartrate.